Loading patent…
OwnerSaid Yous, Mohamed Ettaoussi +6inventors
InventorsSaid Yous, Mohamed Ettaoussi, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
Estimating the term…
Compounds of formula (I): wherein: R1 represents alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, R2 represents a fluorine atom or an alkyl group substituted by one or more fluorine atoms. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.
1-11. (canceled)
12- A compound selected from those of formula (I):
13- The compounds of claim 12, wherein R2 represents a fluorine atom.
14- The compound of claim 12, wherein R2 represents a linear or branched (C1-C6)haloalkyl group.
The compounds of claim 14, wherein R2 represents a fluoromethyl group or a 1-fluoroethyl group.
16- The compound of claim 12, which is N-[3-fluoro-2-(7-methoxy-1-naphthyl)propyl]acetamide, or an addition salt thereof with a pharmaceutically acceptable base.
17- The compound of claim 12, which is N-[4-fluoro-2-(7-methoxy-1-naphthyl)butyl]acetamide, or an addition salt thereof with a pharmaceutically acceptable base.
18- A pharmaceutical composition comprising at least one compound of claim 12, or an addition salt thereof with a pharmaceutically acceptable base, in combination with one or more pharmaceutically acceptable excipients.
19- A method for treating a living animal body, including a human, afflicted with a disorder of the melatoninergic system, comprising the step of administering to the living animal body, including a human, a therapeutically effective amount of the compound of claim 12.
20- A method for treating a living animal body, including a human, afflicted with a condition selected from sleep disorders, stress, anxiety, major depression or seasonal affective disorder, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jetlag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders associated with normal or pathological ageing, migraine, memory loss, Alzheimer's disease, cerebral circulation disorders, sexual dysfunction, a condition requiring an ovulation inhibitor, a condition requiring an immunomodulator, and cancer, comprising the step of administering to the living animal body, including a human, a therapeutically effective amount of the compound of claim 12.
Dependencies are inferred from the claim text.